sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks MK-8776 (SCH 900776)

MK-8776 (SCH 900776)

CAS No.:
891494-63-6
Catalog Number:
AG00GU6F
Molecular Formula:
C15H18BrN7
Molecular Weight:
376.2543
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥95%
1 week
United States
$137
- +
5mg
99%
1 week
United States
$240
- +
10mg
99%
1 week
United States
$323
- +
50mg
99%
1 week
United States
$807
- +
100mg
99%
1 week
United States
$1307
- +
Product Description
Catalog Number:
AG00GU6F
Chemical Name:
MK-8776 (SCH 900776)
CAS Number:
891494-63-6
Molecular Formula:
C15H18BrN7
Molecular Weight:
376.2543
MDL Number:
MFCD20922873
IUPAC Name:
6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3R)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine
InChI:
InChI=1S/C15H18BrN7/c1-22-8-10(6-19-22)11-7-20-23-14(17)12(16)13(21-15(11)23)9-3-2-4-18-5-9/h6-9,18H,2-5,17H2,1H3/t9-/m1/s1
InChI Key:
GMIZZEXBPRLVIV-SECBINFHSA-N
SMILES:
Cn1ncc(c1)c1cnn2c1nc([C@@H]1CCCNC1)c(c2N)Br
UNII:
K2ZSF0992C
Properties
Complexity:
425  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0
Exact Mass:
375.081g/mol
Formal Charge:
0
Heavy Atom Count:
23  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
376.262g/mol
Monoisotopic Mass:
375.081g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
86.1A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
0.8  
Literature
Title Journal
Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity. Toxicological sciences : an official journal of the Society of Toxicology 20131001
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clinical cancer research : an official journal of the American Association for Cancer Research 20121001
Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors. Cell cycle (Georgetown, Tex.) 20120501
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Molecular cancer therapeutics 20120201
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Molecular cancer therapeutics 20110401
Properties